摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol | 137590-29-5

中文名称
——
中文别名
——
英文名称
(-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol
英文别名
(2R)-(hydroxymethyl)-2,3-dihydrobenzopyran;(-)-R-2-hydroxymethylchromane;(R)-chroman-2-ylmethanol;(2R)-2-Hydroxymethyl-chroman;(R)-2-Hydroxymethylchroman;[(2R)-3,4-dihydro-2H-chromen-2-yl]methanol
(-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol化学式
CAS
137590-29-5
化学式
C10H12O2
mdl
——
分子量
164.204
InChiKey
KDLVSGWUKFJFTL-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    293.2±9.0 °C(Predicted)
  • 密度:
    1.125±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    降血糖药恩格列酮的光学活性2-苄基二氢苯并吡喃的合成
    摘要:
    两个合成的某些光学活性的2-苄基-2,3-二氢-4- ħ -benzopyrans和苯并吡喃-4-酮被呈现。从D-和L-苯丙氨酸开始的不对称合成用于提供2-苄基-6-(甲氧基羰基)-2,3-二氢-4 H-苯并吡喃-4-酮19的两种对映体。苯丙氨酸在硫酸水溶液中重氮化。酸转化为2-羟基-3-苯基丙酸6,将其在四个步骤中转化为1-溴-2-(4-甲氧基羰基苯氧基)-3-苯基丙烷11。(4 R,S)-苯甲酰氨基-2-苄基-2, 3-二氢-6-(甲氧基羰基)-4 H -1-苯并吡喃-4-羧酸16由11制备通过在甲磺酸溶液中用α-羟基马尿酸进行酰胺烷基化,然后将其螺烷基化为(4 R,S)-2-苄基-2,3-二氢-6-(甲氧基羰基)螺[4 H-苯并吡喃-4,4'-2 ′-苯恶唑烷] -5′-one 15.将苯恶唑烷-5-酮15水解为螺并苯甲酰胺基羧酸16后,用次氯酸钠氧化脱羧得到旋光的2-苄基-6-(甲氧羰基)-2
    DOI:
    10.1002/jhet.5570290223
  • 作为产物:
    描述:
    苯并二氢吡喃-2-甲酸乙酯 在 sodium tetrahydroborate 作用下, 以 四氢呋喃 为溶剂, 生成 (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol
    参考文献:
    名称:
    降血糖药恩格列酮的光学活性2-苄基二氢苯并吡喃的合成
    摘要:
    两个合成的某些光学活性的2-苄基-2,3-二氢-4- ħ -benzopyrans和苯并吡喃-4-酮被呈现。从D-和L-苯丙氨酸开始的不对称合成用于提供2-苄基-6-(甲氧基羰基)-2,3-二氢-4 H-苯并吡喃-4-酮19的两种对映体。苯丙氨酸在硫酸水溶液中重氮化。酸转化为2-羟基-3-苯基丙酸6,将其在四个步骤中转化为1-溴-2-(4-甲氧基羰基苯氧基)-3-苯基丙烷11。(4 R,S)-苯甲酰氨基-2-苄基-2, 3-二氢-6-(甲氧基羰基)-4 H -1-苯并吡喃-4-羧酸16由11制备通过在甲磺酸溶液中用α-羟基马尿酸进行酰胺烷基化,然后将其螺烷基化为(4 R,S)-2-苄基-2,3-二氢-6-(甲氧基羰基)螺[4 H-苯并吡喃-4,4'-2 ′-苯恶唑烷] -5′-one 15.将苯恶唑烷-5-酮15水解为螺并苯甲酰胺基羧酸16后,用次氯酸钠氧化脱羧得到旋光的2-苄基-6-(甲氧羰基)-2
    DOI:
    10.1002/jhet.5570290223
点击查看最新优质反应信息

文献信息

  • Enantioselective Halo-oxy- and Halo-azacyclizations Induced by Chiral Amidophosphate Catalysts and Halo-Lewis Acids
    作者:Yanhui Lu、Hidefumi Nakatsuji、Yukimasa Okumura、Lu Yao、Kazuaki Ishihara
    DOI:10.1021/jacs.8b02607
    日期:2018.5.16
    Catalytic enantioselective halocyclization of 2-alkenylphenols and enamides have been achieved through the use of chiral amidophosphate catalysts and halo-Lewis acids. Density functional theory calculations suggested that the Lewis basicity of the catalyst played an important role in the reactivity and enantioselectivity. The resulting chiral halogenated chromans can be transformed to α-Tocopherol
    2-烯基苯酚和烯酰胺的催化对映选择性卤环化已经通过使用手性酰胺磷酸盐催化剂和卤代路易斯酸实现。密度泛函理论计算表明催化剂的路易斯碱度在反应性和对映选择性中起重要作用。所得手性卤代色满可以在短时间内转化为 α-生育酚、α-生育三烯酚、代达林 A 和英格列酮。此外,具有不饱和侧链的卤化产物可在自由基环化条件下提供多环加合物。
  • Chirality Transfer in Au-Catalyzed Cyclization Reactions of Monoallylic Diols: Selective Access to Specific Enantiomers Based on Olefin Geometry
    作者:Aaron Aponick、Berenger Biannic
    DOI:10.1021/ol200203k
    日期:2011.3.18
    The gold(I)-catalyzed cyclization of monoallylic diols to form tetrahydropyrans is shown to be highly stereoselective when chiral allylic alcohols are employed. Substrates that differ only in olefin geometry provide enantiomeric products from formal SN2reactions in high yields with excellent chirality transfer. The allylic alcohol stereochemistry also efficiently controls the facial selectivity when
    当使用手性烯丙基醇时,金(I)催化的单烯丙基二醇的环化以形成四氢吡喃显示出高度立体选择性。仅在烯烃几何形状上不同的底物以高收率和良好的手性转移提供了来自正式S N 2'反应的对映体产物。当底物包括另外的立体中心时,烯丙醇的立体化学也有效地控制了面部选择性。
  • (Benzodioxan, benzofuran or benzopyran) derivatives having fundic
    申请人:Janssen Pharmaceutica N.V.
    公开号:US06133277A1
    公开(公告)日:2000-10-17
    The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk.sup.1 is C.sub.1-6 alkanediyl optionally substituted with hydroxy, C.sub.1-4 alkyloxy or C.sub.1-4 alkylcarbonyloxy; --Z.sup.1 --Z.sup.2 -- is a bivalent radical; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6 alkyl, hydroxy, halo and the like; or when R.sup.1 and R.sup.2 are on adjacent carbon atoms, R.sup.1 and R.sup.2 taken together may form a bivalent radical; R.sup.4 is hydrogen or C.sub.1-6 alkyl; A is a bivalent radical of formula --NR.sup.6 --Alk.sup.2 -- (b-1), or --Npiperidinyl--(CH.sub.2).sub.m (b-2) wherein m is 0 or 1; R.sup.5 is a radical of formula ##STR1## wherein n is 1 or 2; p.sup.1 is 0, and p.sup.2 is 1 or 2; or p.sup.1 is 1 or 2, and p.sup.2 is 0; X is oxygen, sulfur or .dbd.NR.sup.9 ; Y is oxygen or sulfur; R.sup.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl or phenylmethyl; R.sup.8 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl phenyl or phenylmethyl; R.sup.9 is cyano, C.sub.1-6 alkyl, C.sub.3-6 cyclo-alkyl, C.sub.1-6 alkyloxycarbonyl or aminocarbonyl; R.sup.10 is hydrogen or C.sub.1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.
    本发明涉及化合物的公式(I),其立体化学异构体形式,N-氧化物形式或药物可接受的酸加成盐形式,其中Alk.sup.1是C.sub.1-6烷二基可选地被羟基,C.sub.1-4烷氧基或C.sub.1-4烷基羧酸基取代; --Z.sup.1 --Z.sup.2 --是一个二价基团; R.sup.1,R.sup.2和R.sup.3各自独立地选择自氢,C.sub.1-6烷基,羟基,卤素等; 或者当R.sup.1和R.sup.2在相邻的碳原子上时,R.sup.1和R.sup.2可以组成一个二价基团; R.sup.4是氢或C.sub.1-6烷基; A是公式--NR.sup.6--Alk.sup.2--(b-1)或--Npiperidinyl--(CH.sub.2).sub.m (b-2)的二价基团,其中m为0或1; R.sup.5是公式##STR1##的基团,其中n为1或2; p.sup.1为0,p.sup.2为1或2; 或者p.sup.1为1或2,p.sup.2为0; X是氧,硫或.dbd.NR.sup.9; Y是氧或硫; R.sup.7是氢,C.sub.1-6烷基,C.sub.3-6环烷基,苯基或苯甲基; R.sup.8是C.sub.1-6烷基,C.sub.3-6环烷基,苯基或苯甲基; R.sup.9是氰基,C.sub.1-6烷基,C.sub.3-6环烷基,C.sub.1-6烷氧羰基或氨基羰基; R.sup.10是氢或C.sub.1-6烷基; Q是一个二价基团。公开了制备所述产品的过程,包含所述产品的制剂以及其作为药物的用途,特别是用于治疗与胃底松弛受损相关的疾病。
  • Lipase-catalysed kinetic resolution of hydroxymethylchromanes
    作者:A. Czompa、T. Kovács、S. Antus
    DOI:10.1002/jhet.5570370450
    日期:2000.7
    An effective kinetic resolution of hydroxymethylchromanes racemic 2a and 3a has been achieved by means of enantioselective transesterification with vinyl acetate in organic solvents. The alcohols (-)-R-2a and (-)-S-3a were obtained with high optical purities (94 and 98% ee) in 70% and 38% yields, respectively. The influence of the enzyme source and the character of the solvent on the enantioselectivity
    通过在有机溶剂中用乙酸乙烯酯进行对映选择性酯交换反应,已实现了羟甲基苯并恶烷外消旋体2a和3a的有效动力学拆分。以高光学纯度(94和98%ee)以70%和38%的产率获得醇(-)- R - 2a和(-)- S - 3a。研究了酶源和溶剂性质对对映选择性的影响。
  • Piperidylmethyl-substituted chroman derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US05326771A1
    公开(公告)日:1994-07-05
    Piperidylmethyl-substituted chroman derivatives can be prepared by first reducing corresponding chromancarboxylic acid derivatives, if appropriate with prior activation, with the cyclic amines and then reducing the carbonyl group, or by reacting chromanmethyl compounds directly with the cyclic amines. The substituted piperidylmethyl-substituted chroman derivatives can be employed as active compounds in medicaments, in particular for the treatment of diseases of the central-nervous system.
    Piperidylmethyl取代的色酮衍生物可以通过首先还原相应的色酮羧酸衍生物(如有必要,可进行先前激活),再与环状胺反应并还原羰基基团,或直接将色酮甲基化合物与环状胺反应来制备。这些取代的Piperidylmethyl取代的色酮衍生物可用作药物的活性成分,特别是用于治疗中枢神经系统疾病。
查看更多